Is ONC a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for BeOne Medicines (ONC) rests on BRUKINSA taking share in B-cell cancers: BRUKINSA global sales reached ~$1.2 billion in the second quarter of 2026, up 31% year over year, with U.S. The bear case rests on concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Analysts covering it publish targets from $370.00 to $528.00 against a $369.15 price, so even the professionals disagree by 36% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
BeOne Medicines is a global oncology company built around one large drug. BRUKINSA (zanubrutinib), a BTK inhibitor used in chronic lymphocytic leukemia and other B-cell cancers, produced ~$1.2 billion of the ~$1.68 billion in product revenue it booked in the second quarter of 2026. Around it sit TEVIMBRA (tislelizumab), a PD-1 antibody; BEQALZI (sonrotoclax), a BCL2 inhibitor that won U.S. accelerated approval in relapsed or refractory mantle cell lymphoma; ZIIHERA (zanidatamab) in HER2-positive gastroesophageal cancer; and in-licensed Amgen products sold in China. The company was BeiGene until recently. Its Nasdaq listing began trading under symbol ONC instead of BGNE on January 2, 2025, and effective May 27, 2025 the company moved its jurisdiction of incorporation from the Cayman Islands to Switzerland and took the BeOne Medicines name. What a U.S. holder actually owns is an American Depositary Share representing 13 ordinary shares, the same shares listed in Hong Kong (06160) and, as RMB shares, on Shanghai's STAR Market (688235). The investment picture is a biotech that has finished crossing into profit. Trailing twelve-month revenue of ~$6.13 billion came with ~$656 million of GAAP net income after years of losses, and management raised 2026 revenue guidance to $6.6 billion to $6.8 billion with GAAP operating income of $1.0 billion to $1.1 billion. Second-quarter gross margin reached 90% of product sales, free cash flow was ~$435 million, and the balance sheet holds ~$5.28 billion of cash against ~$1.07 billion of debt. The argument is over what that stream is worth at roughly 6.8 times trailing sales and about 64 times trailing GAAP earnings. Supporters cite BRUKINSA taking share from Imbruvica and Calquence, a revenue base now ~54% U.S. and only ~30% China, and a deep internally discovered pipeline. Skeptics cite dependence on a single molecule, an AbbVie trade secret suit that survived dismissal, and a company whose research, manufacturing and selling straddle two governments rewriting the rules on each other.
The bull case: what would have to be true for $528.00
The most optimistic published target on ONC is $528.00, +43.0% from the $369.15 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. BRUKINSA taking share in B-cell cancers
BRUKINSA global sales reached ~$1.2 billion in the second quarter of 2026, up 31% year over year, with U.S. sales of ~$893 million growing at the same rate. The share is coming from older BTK inhibitors, principally AbbVie and Johnson & Johnson's Imbruvica and increasingly AstraZeneca's Calquence. Positive Phase 3 MANGROVE results in previously untreated mantle cell lymphoma and 78-month SEQUOIA follow-up in treatment-naive CLL feed first-line submissions the company has guided to in the second half of 2026.
2. Costs growing slower than revenue
Second-quarter revenue rose 30% while total GAAP operating expenses rose 13%, which turned ~$88 million of prior-year GAAP operating income into ~$325 million. SG&A fell to 35% of product sales from 41%, and gross margin improved to 90% as the mix tilted toward global BRUKINSA. Full-year GAAP operating income guidance was raised to $1.0 billion to $1.1 billion, roughly doubling the range given a year earlier.
3. A pipeline meant to outlive one molecule
BEQALZI (sonrotoclax) has now cleared FDA accelerated approval in relapsed or refractory mantle cell lymphoma, and tacabrutideg, the BTK degrader, has a potential Phase 2 submission guided for the second half of 2026. Solid tumor work includes BGB-43395 (CDK4 inhibitor), now in a Phase 3 first-line breast cancer study, plus the B7-H4 antibody-drug conjugate BG-C9074 and the GPC3 bispecific BGB-B2033, both slated for pivotal starts.
4. Revenue mix moving away from China
Second-quarter revenue split ~$914 million U.S., ~$506 million China, ~$209 million Europe and ~$76 million rest of world. Europe grew 37% and rest of world 114%, both faster than China's 17%, of which roughly 7 points came from a stronger renminbi. A company that started as a China biotech now books more than half its revenue in the United States, which changes both its regulatory profile and how the market frames its policy risk.
The bear case: what would have to be true for $370.00
The most pessimistic published target is $370.00, +0.2% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks BeOne Medicines is worth if the risks below bite instead of the drivers above.
Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Zydus filed an ANDA with Paragraph IV certifications against certain BRUKINSA Orange Book patents in early 2026, though it has not challenged the composition of matter patent that runs to 2034. AbbVie's trade secret complaint over the BTK degrader program, including tacabrutideg, survived a motion to dismiss on May 12, 2026 and remains pending with no trial date. About 30% of revenue and a large share of manufacturing and clinical operations sit in China, leaving the company exposed to tariffs, trade-status changes and U.S. or Chinese action against firms with large operations in both. The valuation, near 64 times trailing GAAP earnings on a profit record barely a year old, assumes the growth and the margin improvement both continue.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ONC already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ONC
27 analysts cover ONC, with an average target of $433.02 (+17.3% against $369.15) and a split of 27 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ONC forecast and price target page.
How is ONC valued? (as of August 2026)
Snapshot for ONC as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$6.13B
- Q2 2026 revenue: ~$1.71B, up ~30% year over year
- GAAP net income (TTM): ~$656M (FY2025 was ~$287M, FY2024 a ~$645M loss)
- Q2 2026 diluted EPS per ADS: ~$2.05 GAAP, ~$3.84 adjusted
- Market cap: ~$42B (~113.7M ADSs, about 1.48B ordinary shares)
- Valuation: ~6.8x trailing sales, ~64x trailing GAAP earnings
Figures come from the Form 10-Q for the quarter ended June 30, 2026 and the accompanying Q2 2026 earnings release filed with the SEC on August 5, 2026. The company reports in U.S. dollars, so no conversion is involved despite the Swiss domicile and the Hong Kong and Shanghai listings. Note that per-ADS figures are 13 times the per-ordinary-share figures, which is why a screener showing EPS of $0.16 and one showing $2.12 can both be right.
How do you decide if ONC is a buy?
Rather than asking whether ONC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ONC indirectly through an index or sector ETF before adding more.
What would change your mind on ONC
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: BRUKINSA taking share in B-cell cancers stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ONC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ONC against your real portfolio and see your actual exposure before deciding.
Investing in BeOne Medicines with AI
Connect the broker you already use and ask Walnut's AI how ONC fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is ONC a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on BRUKINSA taking share in B-cell cancers, with revenue (ttm) at ~$6.13B. The bear case rests on concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Analysts covering it are spread from $370.00 to $528.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ONC?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $370.00, +0.2% from the $369.15 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for ONC?
+
BRUKINSA taking share in B-cell cancers. BRUKINSA global sales reached ~$1.2 billion in the second quarter of 2026, up 31% year over year, with U.S. The most optimistic analyst target on ONC is $528.00, +43.0% from the $369.15 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ONC?
+
Concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business. Zydus filed an ANDA with Paragraph IV certifications against certain BRUKINSA Orange Book patents in early 2026, though it has not challenged the composition of matter patent that runs to 2034. AbbVie's trade secret complaint over the BTK degrader program, including tacabrutideg, survived a motion to dismiss on May 12, 2026 and remains pending with no trial date. About 30% of revenue and a large share of manufacturing and clinical operations sit in China, leaving the company exposed to tariffs, trade-status changes and U.S. or Chinese action against firms with large operations in both. The valuation, near 64 times trailing GAAP earnings on a profit record barely a year old, assumes the growth and the margin improvement both continue. The most pessimistic published target is $370.00, +0.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does BeOne Medicines do?
+
BeOne Medicines, the Swiss-domiciled oncology company formerly known as BeiGene, is built around BRUKINSA, a BTK inhibitor taking share in blood cancers.
What would have to change for ONC to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (BRUKINSA taking share in B-cell cancers) stalling in the reported numbers rather than in the narrative, the risk above (concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does BeOne Medicines do?
+
BeOne discovers, develops, manufactures and sells cancer medicines worldwide. Its lead product is BRUKINSA (zanubrutinib), a BTK inhibitor for B-cell blood cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. It also sells the PD-1 antibody TEVIMBRA, the BCL2 inhibitor BEQALZI, ZIIHERA in HER2-positive gastroesophageal cancer, and several in-licensed Amgen products in China.
How does BeOne make money?
+
Almost entirely from product sales. Net product revenue was ~$1.68 billion in the second quarter of 2026, of which BRUKINSA was ~$1.2 billion, TEVIMBRA ~$229 million and the Amgen in-licensed products ~$157 million. Other revenue, mostly collaboration income, was ~$25 million. Gross margin on product sales ran at 90% in the quarter.
What is the full legal company name behind the ticker ONC?
+
BeOne Medicines Ltd., known in German as BeOne Medicines AG, incorporated in Switzerland with offices at Aeschengraben 27 in Basel. It was BeiGene, Ltd., a Cayman Islands company, until the redomiciliation took effect on May 27, 2025. The Nasdaq ticker changed from BGNE to ONC earlier, on January 2, 2025. Its SEC filer identifier is CIK 0001651308.
Walnut is informational, not investment advice, and gives no verdict on ONC. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.